Dysfunctional uterine bleeding. Clarifying its definition, mechanisms, and management.
"Dysfunctional uterine bleeding" is not a generic term for abnormal uterine bleeding. Rather, it refers solely to bleeding caused by an ovarian endocrinopathy. Estrogen withdrawal and inappropriately sustained estrogen production are the two mechanisms responsible. The latter mechanism produces estrogen breakthrough bleeding, which is common in women with chronic anovulation. Treatment of estrogen withdrawal bleeding depends on when in the menstrual cycle bleeding occurs. Anovulatory bleeding is best treated with progestin. Estrogen therapy is contraindicated, except in patients with profuse anovulatory bleeding unresponsive to progestin treatment, because it increases the risk of endometrial hyperplasia and cancer.
D000230:Adenocarcinoma / Q000209:etiology; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D001831:Body Temperature; D004359:Drug Therapy, Combination; D004702:Endocrine Glands / Q000503:physiopathology; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D006801:Humans; D008597:Menstrual Cycle; D011372:Progestins / Q000008:administration & dosage; D012306:Risk; D014592:Uterine Hemorrhage / Q000188:drug therapy / Q000503:physiopathology*; D014594:Uterine Neoplasms / Q000209:etiology
D004967:Estrogens; D011372:Progestins